Drugs / VERVE-102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06164730 | Apr 2024 → Aug 2026 overdue | coronary artery disorder, familial hypercholesterolemia | Verve Therapeutics, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-05-25 | Eli Lilly and Company | Results A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia lilly.com ↗
Eli Lilly and Company (NYSE: LLY) today announced positive Phase 1b Heart-2 study results for VERVE-102, an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in the liver and lower blood low-density lipoprotein cholesterol (LDL-C) following a single infusion. |
| 2025-04-14 | Verve Therapeutics, Inc. | Results Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9 vervetx.com ↗
Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102. |
| 2025-04-11 | Verve Therapeutics, Inc. | Regulatory Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9 vervetx.com ↗
Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VERVE-102 for the treatment of patient groups with hyperlipidemia and high lifetime cardiovascular risk to reduce low-density lipoprotein cholesterol (LDL-C). |
| 2025-03-24 | Verve Therapeutics, Inc. | Regulatory Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose vervetx.com ↗
Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for VERVE-102 for the treatment of patients living with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD). |
| 2024-08-08 | Verve Therapeutics, Inc. | Regulatory Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results vervetx.com ↗
Our Heart-2 Phase 1b clinical trial of VERVE-102 continues to progress as we focus on enrolling patients and expanding the trial’s geographic footprint, highlighted by our recent regulatory clearance in Australia. |
| 2024-04-02 | Verve Therapeutics, Inc. | Regulatory Verve Therapeutics Announces Updates on its PCSK9 Program vervetx.com ↗
Clinical Trial Applications have been cleared by the U.K. MHRA and Health Canada |
All press releases naming this drug 7 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VERVE-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06164730 ↗ |
| Action | Inhibit | “designed to durably inactivate PCSK9 in the liver” PMID 42187087 ↗ May 2026 |
| Route | Intravenous | “we administered one intravenous infusion of VERVE-102 at one of six doses (ranging from 0.3 to 1.0 mg of total RNA per kilogram of body weight [mg per kilogram])” PMID 42187087 ↗ May 2026 |